This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.

Efficacy and Safety Profile: Haemodialysis and Haemofiltration

Renal Patients: Efficacy and Safety Profile

Schmid P et al. Swiss Med Wkly 2009;139:438–4521.

Study Design:

A critical review of published data regarding the pharmacokinetic properties of low molecular weight heparin (LMWH) used for the treatment of patients with renal insufficiency.


In general, LMWH are more effective and have  a lower bleeding risk than UFH. In addition, LMWH have bioavailability of >85% after s.c. injection; in contrast, s.c. administered UFH has bioavailability of 15–40% with wide variability. LMWHs such as Fragmin may be considered for patients with severe renal insufficiency for up to 10 days, with careful monitoring. 


LMWH may be suitable for patients with severe renal insufficiency. Careful monitoring of bioaccumulation (anti-Xa levels) is necessary.

Douketis J et al. Arch Intern Med 2008;168:1805–1812 (DIRECT)2.

Study Design:

Prospective, multicentre, single-arm, open-label clinical trial to determine if DVT prophylaxis with Fragmin conferred an excessive anticoagulant effect in critically-ill patients with severe renal insufficiency (N=138). 5,000 IU Fragmin was administered o.d. in patients with CrCl <30 mL/min; pharmacokinetic properties were assessed by serial anti-Xa levels measured on days 3, 10 and 17.

Primary endpoint:

Trough and peak anti-Xa levels, measured on days 3, 10 and 17.


The median duration of Fragmin exposure was 7 (IQR = 4–12) days. 120 patients had at least 1 trough anti-Xa level, and none had bioaccumulation, defined by a trough anti-Xa level higher than 0.40 IU/mL (0%; 95% CI, 0%–3.0%).

Asymptomatic DVT developed in 5.1% of patients (n=7; 95% CI, 2.5%–10.1%); major bleeding occurred in 7.2% of patients (n=10; 95% CI, 4.0%–12.8%), all with trough anti-Xa levels of 0.18 IU/mL or lower. Mean CrCl at baseline and at the end of Fragmin prophylaxis was 18.9 mL/min and 28.4 mL/min, respectively.


DVT prophylaxis with Fragmin for 7 days was not associated with bioaccumulation or excessive anticoagulant effect.

Monreal M et al. Am J Med 2006;119:1073–1079 (RIETE)3.

Study Design:

RIETE is a prospective registry of patients with symptomatic acute VTE. This analysis retrospectively analysed the effect of renal insufficiency on the incidence of fatal PE and fatal bleeding within 15 days of diagnosis. Patients (N=10,526) were grouped as follows: 88.0% had a CrCl >60 mL/min (n=9,234), 6.7% had a CrCl 30–60 mL/min (n=704), and 5.6% had a CrCl <30 mL/min (n=588). Mean initial daily doses of LMWH and UFH were similar in the 3 patient groups.

Primary endpoint:

Incidence of death due to PE or bleeding.


The incidence of major bleeding was significantly higher in the abnormal groups (CrCl 30–60 mL/min and CrCl <30 mL/min), whereas the incidence of VTE recurrences was similar in all three subgroups.

The incidence of fatal PE during the study was 1.0%, 2.6%, and 6.6%, across the CrCl >60 mL/min, CrCl 30-60 mL/min and CrCl <30 mL/min groups, respectively. In addition, the use of UFH was associated with a significantly higher risk of fatal PE compared with LMWH. Fatal bleeding occurred in 0.2%, 0.3% and 1.2% of patients from the CrCl >60 mL/min, CrCl 30–60 mL/min and CrCl <30 mL/min groups, respectively.

Multivariate analysis confirmed that decreasing CrCl, cancer and immobility for 4 days or more were independently associated risk factors for fatal PE and fatal bleeding.


Patients with VTE and renal insufficiency had an increased incidence of both fatal PE and fatal bleeding, but the risk of fatal PE far exceeded that of fatal bleeding.

Schmid P et al. J Thromb Haemost 2009;7:552–5584.

Study Design:

Prospective cohort study, comparing pharmacokinetic data for Fragmin for up to three weeks in patients with varying degrees of renal insufficiency. Patients were grouped according to renal function: normal (GFR =60 mL/min/1.73m2; N=18), mild (GFR 30–59 mL/min/1.73m2; N=15) or severe (GFR <30 mL/min/1.73m2; N=9). Fragmin was injected s.c once daily at a prophylactic dose. Peak anti-Xa activity levels were measured 4 hours after injection on Day 1 and every third day up to 3 weeks.

Primary endpoint:

Peak anti-Xa levels and adjusted anti-Xa levels (adjustment being carried out for dose and body weight).


A total of 42 patients could be analysed during a median of 10 days (IQR = 4–13, range 1–20). In all groups, adjusted peak anti-Xa levels were not significantly different on Day 10 compared with Day 1. No bioaccumulation >30% (the statistical detection threshold) could be found up to Day 10 in any of the groups.


The use of Fragmin at a prophylactic dose was not associated with a bioaccumulation >30%, even in patients with severe renal insufficiency during a median follow-up of 10 days.

Shprecher AR et al. Pharmacotherapy 2005;25:817–8225.

Study Design:

Prospective, single-centre, open-label, unblinded, comparative study to determine the relationship between impaired renal function and anti-Xa activity in patients requiring therapeutic anticoagulation. Fragmin at a dose of ~100 U/kg was administered s.c. twice daily to patients with renal insufficiency (CrCl < 40mL/min, N=11) and patients without renal insufficiency (CrCl >80 mL/min, N=11). This study assessed whether anti-Xa activity was meaningfully greater in the group with renal insufficiency vs the group with normal renal function.

Primary endpoint:

Peak anti-Xa levels.


Mean ± SD levels were similar for patients with and without renal insufficiency: 0.47 ± 0.25 and 0.55 ± 0.20 U/mL respectively. This difference was not statistically significant. No trend was identified for anti-Xa activity levels by BMI. No serious adverse events occurred and no patients were withdrawn from the study.


Fragmin was well tolerated in patients with renal insufficiency and in control subjects; there was no significant difference in peak anti-Xa activity between both groups.

Tincani E et al. Haematologica 2006;91:976–9796.

Study Design:

Prospective cohort study to determine the incidence of Fragmin bioaccumulation and bleeding complications during thromboprophylaxis in elderly patients (N=115) with renal failure admitted to hospital with an acute medical illness. Fragmin was administered s.c. once daily, at a dose of 5,000 IU in patients at high VTE risk, and 2,500 IU in patients at low risk. Anti-Xa activity was determined before the first dosage and on Day 6 of treatment; bleeding was assessed daily.

Primary endpoint:

Anti-Xa activity on Day 6 of Fragmin treatment.


Anti-Xa levels before the first dose of Fragmin were undetectable and there was no relationship between the degree of renal insufficiency and the peak anti-Xa level at Day 6.
There were no major bleeding events; no symptomatic VTE events and no asymptomatic DVT were recorded (95% CI, 0% to 2.5%). Of the 115 patients, 3 (2.7%) had minor haemorrhages (95% CI, 0.6% to 6.7%).


Fragmin thromboprophylaxis in elderly patients admitted with an acute medical illness who have renal insufficiency was associated with a low risk of both bioaccumulation and bleeding.

Haemodialysis and Haemofiltration

Fragmin Tolerability

Find out more

Using Fragmin Needle-Trap

Click below to learn how to use a Fragmin Needle-Trap

Learn more

Categories of Anticoagulants

Find out more

Patient Resources

Discover our range of patient resources

Discover more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?